0.00Open0.05Pre Close0 Volume152 Open Interest12.50Strike Price0.00Turnover2653.08%IV19.21%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0396Delta0.0291Gamma308.20Leverage Ratio-7.4912Theta0.0000Rho-12.19Eff Leverage0.0001Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet